In this Review, we appraise innovative point-of-care devices that enable the early diagnosis of DPN and assess the evidence for early risk factor-based management strategies to reduce the incidence and slow the progression of DPN (The Lancet Diabetes & Endocrinology)
Diabetes News
Category: Neuropathy
Electrophysiological Characterization of Neuropathy Complicating Type 1 Diabetes Mellitus
These findings signify generation of a protocol for early screening of neuropathy in children with type 1 diabetes (Journal of Diabetes Research)
Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review
This review evaluates the role of pregabalin in the management of pDPN as well as its potential adverse effects, such as somnolence and dizziness, which can lead to withdrawal in ~ 30% of long-term use (Diabetes Therapy)
Neuropad for detecting preclinical diabetic peripheral neuropathy
The case for adopting Neuropad to detect preclinical diabetic peripheral neuropathy is not supported by the evidence (NICE)
Reduced vitamin D levels in painful diabetic peripheral neuropathy
We have demonstrated a significant difference in 25‐hydroxyvitamin D levels in well‐characterized people with painful diabetic peripheral neuropathy, while accounting for the main confounding factors. This suggests a possible role for vitamin D in the pathogenesis of painful diabetic peripheral neuropathy (Diabetic Medicine)
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients
In this review, we seek to illuminate the relationships among T2D, diabetic peripheral neuropathy, and OSA and how they interact with one another (Journal of Diabetes Research)
Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark
Both higher levels and slopes of HbA1c trajectories were associated with DPN after 13 years. Our findings indicate that the rate of HbA1c increase affects the development of DPN over and above the effect of the HbA1c level. Furthermore, this study supports obesity as a risk factor for DPN (Diabetes Care)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)
In patients with type 2 diabetes and moderate-to-severe chronic kidney disease, once-weekly dulaglutide produced glycaemic control similar to that achieved with insulin glargine, with reduced decline in eGFR. Dulaglutide seems to be safe to use to achieve glycaemic control in patients with moderate-to-severe chronic kidney disease (The Lancet Diabetes & Endocrinology)
Neuropathic pain in adults: pharmacological management in non-specialist settings
The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management (NICE)
HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients
Increased HbA1c variability is closely associated with DPN in type 2 diabetic patients and could be considered as a potent indicator for DPN in these patients (BMC Health Services Research)
Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT Study)
Around half of participants in an educational initiative had DSPN, 62% of whom had the painful entity that correlated with BMI in T2D. Since many cases of neuropathy and diabetes remain undiagnosed, effective strategies to timely detect both conditions should be implemented (Diabetes Research and Clinical Practice)
The Role of Oxidative Stress, Mitochondrial Function, and Autophagy in Diabetic Polyneuropathy
Clarification of the mechanisms involved in the appearance of complications in DM will facilitate the selection of specific therapeutic options based on the mechanisms involved in the metabolic pathways affected (Journal of Diabetes Research)
Neuropathic pain in adults: pharmacological management in non-specialist settings
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living (NICE)
Lipids: A Suitable Therapeutic Target in Diabetic Neuropathy?
Future research should concentrate on targeting lipids with one or more aggressive interventions specifically in patients with DM2 whose DPN is detectable but whose progression can still be largely prevented (Journal of Diabetes Research)
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
This Position Statement is based on several recent technical reviews, to which the reader is referred for detailed discussion and relevant references to the literature (Diabetes Care)
Diabetic Neuropathy
A Position Statement by the American Diabetes Association (Diabetes Care)
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function
Treatment should be directed to improve etiologic factors besides reducing symptoms; several approaches have been evaluated to reduce neuropathic impairments and improve nerve conduction, such as oral antidiabetics, statins, and antioxidants (Journal of Diabetes Research)
Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes
In this cross-sectional analysis, copeptin was strongly associated with diabetic kidney disease and coronary atherosclerosis in adults with T1D. Further research is needed to determine whether these relationships hold true longitudinally in people with T1D (Journal of Diabetes and Its Complications)
Impaired Awareness of Hypoglycemia in Adults With Type 1 Diabetes Is Not Associated With Autonomic Dysfunction or Peripheral Neuropathy
In adults with type 1 diabetes, IAH was not associated with autonomic dysfunction or peripheral neuropathy (Diabetes Care)
Corneal Confocal Microscopy Predicts 4-Year Incident Peripheral Neuropathy in Type 1 Diabetes
DPN can be predicted by various demographic, metabolic, and conventional neuropathy measures. The ability of CCM to predict DPN broadens the already impressive diagnostic capabilities of this novel ophthalmic marker (Diabetes Care)
Glycosmedia is also available as an App: